Scynexis announced that the FDA has designated SCY-078 a Qualified Infectious Disease Product (QDIP) for the treatment of invasive Candidiasis, including Candidemia and  Aspergillosis. SCY-078 (formerly MK-3118), a semi-synthetic derivative of the natural product enfumafungin is an oral glucan synthase inhibitor.

Glucan synthase inhibitors have been effective in treating invasive fungal infections in a hospital setting but are currently only available in intravenous formulations. Multiple Phase 1 studies have been completed on this novel compound.

RELATED: Infectious Disease Resource Center

SCY-078 is currently entering into Phase 2 trials and has shown activity against the two main pathogens responsible for the majority of invasive fungal infections (IFI), Candida and Aspergillus species.

Continue Reading

For more information call (919) 544-8600 or visit